NEKTAR THERAPEUTICS Raises $400M in Public Offering

By Chris Stiles • Friday, February 13 10:56 • Permanent Link

Nektar Therapeutics, a clinical-stage biotechnology company, recently announced the pricing of an upsized underwritten public offering of $400 million of shares of its common stock. The company sold 6,603,449 shares of common stock at a public offering price of $58.00 per share and 293,103 pre-funded warrants at a public offering price of $57.9999 per pre-funded warrant. The gross proceeds to Nektar from the offering are expected to be approximately $400 million.

The company also granted the underwriters a 30-day option to purchase up to an additional 1,034,482 shares of its common stock at the public offering price per share. The offering is expected to close on February 13, 2026, subject to the satisfaction of customary conditions.

Nektar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, clinical development, and manufacturing costs to support the advancement of its drug candidates, as well as other general corporate purposes.

The securities were offered pursuant to a shelf registration statement on Form S-3ASR (No. 333-291466) that was filed with the U.S. Securities and Exchange Commission on November 12, 2025, and automatically became effective upon filing.

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases. Its lead product candidate, rezpegaldesleukin, is being evaluated in phase 2b clinical trials for atopic dermatitis, alopecia areata, and type 1 diabetes mellitus. The company's pipeline also includes other promising drug candidates such as a preclinical bivalent tumor necrosis factor receptor type II antibody and bispecific programs, as well as an investigational IL-15 receptor agonist, nktr-255, designed to boost the immune system's ability to fight cancer.

The company is headquartered in San Francisco, California. The market has reacted to these announcements by moving the company's shares 6.56% to a price of $37.68. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.